Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Alumis Inc (ALMS)

Alumis Inc (ALMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire - Fri Jan 9, 3:05PM CST

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 22.11 (+4.84%)
Alumis Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire - Wed Jan 7, 9:52PM CST

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 22.11 (+4.84%)
Stock exchange financial or forex graph by Bigc Studio via Shutterstock
Should You Chase the Rally in Alumis Stock Today? Barchart - Wed Jan 7, 10:35AM CST

Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.

JNJ : 213.65 (+1.87%)
ALMS : 22.11 (+4.84%)
BMY : 55.92 (+0.27%)
Alumis Announces Proposed Public Offering of Common Stock GlobeNewswire - Tue Jan 6, 3:12PM CST

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 22.11 (+4.84%)
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program GlobeNewswire - Tue Jan 6, 6:00AM CST

– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved...

ALMS : 22.11 (+4.84%)
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis GlobeNewswire - Mon Jan 5, 4:00PM CST

– Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma...

ALMS : 22.11 (+4.84%)
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress GlobeNewswire - Thu Nov 13, 2025

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 22.11 (+4.84%)
Alumis to Participate in Upcoming November Investor Conferences GlobeNewswire - Tue Nov 4, 2025

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 22.11 (+4.84%)
Alumis to Participate in Upcoming September Investor Conferences GlobeNewswire - Fri Aug 29, 2025

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated...

ALMS : 22.11 (+4.84%)
Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Wed Aug 13, 2025

–Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026– –Completed enrollment in Phase 2b...

ALMS : 22.11 (+4.84%)

Barchart Exclusives

Should You Buy Dividend-Paying Gold Stocks as Trump Makes Them ‘Great Again’? Barchart - Tue Jan 13, 6:30PM CST
Gold stocks have soared over the last year amid the rally in gold prices. Miners are paying handsome dividends as their cash flows have tracked gold prices higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot